Dave AspreyEntrepreneur, author and podcast host · founder and CEO of Upgrade Labs · no clinical or scientific credential claimed
Access, and it is getting cheaper
What it rests onHis own treatment history across multiple countries, and the arrival of domestic providers that removed the need to travel and pay $40,000 to $100,000 abroad.
Source: daveasprey.com ↗
Paul KnoepflerPhD · Professor of Cell Biology and Human Anatomy, UC Davis School of Medicine · stem cell and cancer biologist
A problem, and the growth is the evidence
What it rests onPeer-reviewed marketplace surveys: a cohort of 570 unproven clinics tracked over three years, and a website count that at least doubled every year from 2009 to 2014 while FDA action stayed minimal.
Source: sciencebasedmedicine.org ↗
Asprey is describing what is purchasable by someone with money and a high risk tolerance. Knoepfler is describing what is marketed to people with serious untreatable conditions, which is a different customer with a different downside.
Both agree the US market grew rapidly and is now large and domestic rather than offshore. Neither disputes the count.
Outcome data. Both positions currently rest on market structure rather than on what happened to the patients, which is the gap Knoepfler's own papers say the field has not filled.
You do, and your call is dated, kept, and yours to change. Follow the people you already trust and what they publish turns into a short daily practice.
Free to sign up and use. We do not ask for a card.